Induction of DISE in ovarian cancer cells in vivo

Andrea E. Murmann, Kaylin M. McMahon, Ashley Haluck-Kangas, Nandini Ravindran, Monal Patel, Calvin Y. Law, Sonia Brockway, Jian Jun Wei, C. Shad Thaxton, Marcus E. Peter*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

The death receptor CD95/Fas can be activated by immune cells to kill cancer cells. shRNAs and siRNAs derived from CD95 or CD95 ligand (CD95L) are highly toxic to most cancer cells. We recently found that these sh/siRNAs kill cancer cells in the absence of the target by targeting the 3'UTRs of critical survival genes through canonical RNAi. We have named this unique form of off-target effect DISE (for death induced by survival gene elimination). DISE preferentially kills transformed cells and cancer stem cells. We demonstrate that DISE induction occurs in cancer cells in vivo after introducing a lentiviral CD95L derived shRNA (shL3) into HeyA8 ovarian cancer cells grown as i.p. xenografts in mice, when compared to a scrambled shRNA. To demonstrate the possibility of therapeutically inducing DISE, we coupled siRNAs to templated lipoprotein nanoparticles (TLP). In vitro, TLPs loaded with a CD95L derived siRNA (siL3) selectively silenced a biosensor comprised of Venus and CD95L ORF and killed ovarian cancer cells. In vivo, two siRNA-TLPs (siL2-TLP and siL3-TLP) reduced tumor growth similarly as observed for cells expressing the shL3 vector. These data suggest that it is possible to kill ovarian cancer cells in vivo via DISE induction using siRNA-TLPs.

Original languageEnglish (US)
Pages (from-to)84643-84658
Number of pages16
JournalOncotarget
Volume8
Issue number49
DOIs
StatePublished - Oct 17 2017

Keywords

  • Cell death
  • Fas
  • Ovarian cancer
  • RNAi
  • TLP nanoparticles

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Induction of DISE in ovarian cancer cells in vivo'. Together they form a unique fingerprint.

Cite this